Overview
- Anonymous sources say the White House is considering a Section 301 investigation of foreign drug pricing practices that could lead to tariffs or other trade actions on pharmaceuticals.
- The Financial Times first reported the plan and the White House declined to comment on the discussions.
- The administration’s stated goal is to push other countries to align their medicine prices with U.S. levels, a dynamic it has criticized as “global freeloading.”
- Section 301 gives the president authority to respond to perceived unfair foreign practices and has been used for multi-country issues such as digital services taxes.
- The reported plan follows a shelved threat of a 100% tariff on branded drugs and earlier steps including an executive order on lowest-price matching and letters pressing 17 companies to cut Medicare prices.